{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T22:59:14Z","timestamp":1791845954475,"version":"4.3.4"},"reference-count":83,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,26]],"date-time":"2023-03-26T00:00:00Z","timestamp":1679788800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.biopha.2023.114614","type":"journal-article","created":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T11:25:36Z","timestamp":1680002736000},"page":"114614","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["FDA approved drugs with antiviral activity against SARS-CoV-2: From structure-based repurposing to host-specific mechanisms"],"prefix":"10.1016","volume":"162","author":[{"given":"Mahmoud S.","family":"Ahmed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayman B.","family":"Farag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian N.","family":"Boys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Menendez-Montes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ngoc Uyen Nhi","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Eitson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maikke B.","family":"Ohlson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenchun","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew B.","family":"McDougal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrina","family":"Mar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suwannee","family":"Thet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo Young","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Solmonson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noelle S.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Lemoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph J.","family":"DeBerardinis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W.","family":"Schoggins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hesham A.","family":"Sadek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.biopha.2023.114614_bib1","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1080\/01652176.2020.1727993","article-title":"Emerging novel coronavirus (2019-nCoV)-current scenario, evolutionary perspective based on genome analysis and recent developments","volume":"40","author":"Malik","year":"2020","journal-title":"Vet. Q"},{"issue":"7798","key":"10.1016\/j.biopha.2023.114614_bib2","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41586-020-2008-3","article-title":"A new coronavirus associated with human respiratory disease in China","volume":"579","author":"Wu","year":"2020","journal-title":"Nature"},{"issue":"7798","key":"10.1016\/j.biopha.2023.114614_bib3","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2023.114614_bib4","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/7341493","article-title":"Paxlovid: mechanism of action, synthesis, and in silico study","volume":"2022","author":"Marzi","year":"2022","journal-title":"Biomed. Res Int"},{"issue":"15","key":"10.1016\/j.biopha.2023.114614_bib5","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","article-title":"Oral nirmatrelvir for high-risk, nonhospitalized adults with covid-19","volume":"386","author":"Hammond","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"7943","key":"10.1016\/j.biopha.2023.114614_bib6","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/d41586-022-04576-6","article-title":"COVID drug Paxlovid was hailed as a game-changer. What happened?","volume":"613","author":"Kozlov","year":"2023","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.biopha.2023.114614_bib7","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jiph.2021.12.014","article-title":"The SARS-CoV-2 mutations versus vaccine effectiveness: new opportunities to new challenges","volume":"15","author":"Malik","year":"2022","journal-title":"J Infect. Public Health"},{"issue":"1","key":"10.1016\/j.biopha.2023.114614_bib8","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41392-021-00623-2","article-title":"SARS-CoV-2 mutations, vaccines, and immunity: implication of variants of concern","volume":"6","author":"Noh","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"issue":"7816","key":"10.1016\/j.biopha.2023.114614_bib9","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/s41586-020-2286-9","article-title":"A SARS-CoV-2 protein interaction map reveals targets for drug repurposing","volume":"583","author":"Gordon","year":"2020","journal-title":"Nature"},{"issue":"6521","key":"10.1016\/j.biopha.2023.114614_bib10","doi-asserted-by":"crossref","first-page":"eabe9403","DOI":"10.1126\/science.abe9403","article-title":"Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms","volume":"370","author":"Gordon","year":"2020","journal-title":"Science"},{"issue":"7811","key":"10.1016\/j.biopha.2023.114614_bib11","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41586-020-2223-y","article-title":"Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors","volume":"582","author":"Jin","year":"2020","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.biopha.2023.114614_bib12","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/s41589-020-00689-z","article-title":"SARS-CoV-2 Mpro inhibitors and activity-based probes for patient-sample imaging","volume":"17","author":"Rut","year":"2021","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.biopha.2023.114614_bib13","first-page":"eabg5827","article-title":"Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2","author":"Drayman","year":"2021","journal-title":"Science"},{"issue":"50","key":"10.1016\/j.biopha.2023.114614_bib14","doi-asserted-by":"crossref","first-page":"eabe0751","DOI":"10.1126\/sciadv.abe0751","article-title":"Structure and inhibition of the SARS-CoV-2 main protease reveal strategy for developing dual inhibitors against Mpro and cathepsin L","volume":"6","author":"Sacco","year":"2020","journal-title":"Sci. Adv."},{"issue":"6536","key":"10.1016\/j.biopha.2023.114614_bib15","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1126\/science.abf1611","article-title":"SARS-CoV-2 Mpro inhibitors with antiviral activity in a transgenic mouse model","volume":"371","author":"Qiao","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.biopha.2023.114614_bib16","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.cegh.2020.07.011","article-title":"Remdesivir and its antiviral activity against COVID-19: a systematic review","volume":"9","author":"Frediansyah","year":"2021","journal-title":"Clin. Epidemiol. Glob. Health"},{"issue":"43","key":"10.1016\/j.biopha.2023.114614_bib17","doi-asserted-by":"crossref","first-page":"26955","DOI":"10.1073\/pnas.2014441117","article-title":"Favipiravir at high doses has potent antiviral activity in SARS-CoV-2\u2212infected hamsters, whereas hydroxychloroquine lacks activity","volume":"117","author":"Kaptein","year":"2020","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"Pt A","key":"10.1016\/j.biopha.2023.114614_bib18","article-title":"Tocilizumab for treatment patients with COVID-19: recommended medication for novel disease","volume":"89","author":"Samaee","year":"2020","journal-title":"Int Immunopharmacol."},{"issue":"1","key":"10.1016\/j.biopha.2023.114614_bib19","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s12967-020-02339-3","article-title":"Why tocilizumab could be an effective treatment for severe COVID-19?","volume":"18","author":"Fu","year":"2020","journal-title":"J. Transl. Med."},{"issue":"10349","key":"10.1016\/j.biopha.2023.114614_bib20","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0140-6736(22)01109-6","article-title":"Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis","volume":"400","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2023.114614_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101489","article-title":"Baricitinib in hospitalised patients with COVID-19: a meta-analysis of randomised controlled trials","volume":"49","author":"Selvaraj","year":"2022","journal-title":"eClinicalMedicine"},{"issue":"2","key":"10.1016\/j.biopha.2023.114614_bib22","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"issue":"6483","key":"10.1016\/j.biopha.2023.114614_bib23","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1126\/science.abb2507","article-title":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation","volume":"367","author":"Wrapp","year":"2020","journal-title":"Science"},{"issue":"6485","key":"10.1016\/j.biopha.2023.114614_bib24","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1126\/science.abb2762","article-title":"Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2","volume":"367","author":"Yan","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.biopha.2023.114614_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.molcel.2020.04.022","article-title":"A multibasic cleavage site in the spike protein of SARS-CoV-2 is essential for infection of human lung cells","author":"Hoffmann","year":"2020","journal-title":"Mol. Cell"},{"key":"10.1016\/j.biopha.2023.114614_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.biopha.2023.114614_bib27","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.virusres.2006.01.017","article-title":"Nidovirales: evolving the largest RNA virus genome","volume":"117","author":"Gorbalenya","year":"2006","journal-title":"Virus Res"},{"key":"10.1016\/j.biopha.2023.114614_bib28","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.antiviral.2014.12.015","article-title":"The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds","volume":"115","author":"Baez-Santos","year":"2015","journal-title":"Antivir. Res"},{"issue":"21","key":"10.1016\/j.biopha.2023.114614_bib29","doi-asserted-by":"crossref","first-page":"12359","DOI":"10.1021\/acs.jmedchem.0c00606","article-title":"COVID-19: drug targets and potential treatments","volume":"63","author":"Gil","year":"2020","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.biopha.2023.114614_bib30","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1021\/acscentsci.0c00272","article-title":"Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases","volume":"6","author":"Liu","year":"2020","journal-title":"ACS Central Sci."},{"key":"10.1016\/j.biopha.2023.114614_bib31","doi-asserted-by":"crossref","unstructured":"Farag, A., et al., Identification of FDA approved drugs targeting COVID-19 virus by structure-based drug repositioning. 2020.","DOI":"10.26434\/chemrxiv.12003930.v2"},{"key":"10.1016\/j.biopha.2023.114614_bib32","doi-asserted-by":"crossref","first-page":"22677","DOI":"10.1038\/srep22677","article-title":"Structure of main protease from human coronavirus NL63: insights for wide spectrum anti-coronavirus drug design","volume":"6","author":"Wang","year":"2016","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.biopha.2023.114614_bib33","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1007\/s00894-014-2122-y","article-title":"Investigation on the mechanism for the binding and drug resistance of wild type and mutations of G86 residue in HIV-1 protease complexed with Darunavir by molecular dynamic simulation and free energy calculation","volume":"20","author":"Li","year":"2014","journal-title":"J. Mol. Model"},{"issue":"1","key":"10.1016\/j.biopha.2023.114614_bib34","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2174\/157340607779317490","article-title":"Metabolism of moexipril to moexiprilat: determination of in vitro metabolism using HPLC-ES-MS","volume":"3","author":"Kalasz","year":"2007","journal-title":"Med Chem."},{"key":"10.1016\/j.biopha.2023.114614_bib35","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1038\/ncomms2921","article-title":"Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin","volume":"4","author":"Pang","year":"2013","journal-title":"Nat. Commun."},{"issue":"22","key":"10.1016\/j.biopha.2023.114614_bib36","doi-asserted-by":"crossref","first-page":"10630","DOI":"10.1093\/nar\/gkt828","article-title":"On the structural basis and design guidelines for type II topoisomerase-targeting anticancer drugs","volume":"41","author":"Wu","year":"2013","journal-title":"Nucleic Acids Res"},{"issue":"9","key":"10.1016\/j.biopha.2023.114614_bib37","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1097\/FPC.0000000000000157","article-title":"Genetic determinants of metamizole metabolism modify the risk of developing anaphylaxis","volume":"25","author":"Garcia-Martin","year":"2015","journal-title":"Pharm. Genom."},{"issue":"1","key":"10.1016\/j.biopha.2023.114614_bib38","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s12104-011-9316-3","article-title":"Backbone and side-chain (1)H, (1)(5)N, and (1)(3)C resonance assignments of Norwalk virus protease","volume":"6","author":"Takahashi","year":"2012","journal-title":"Biomol. NMR Assign."},{"issue":"5","key":"10.1016\/j.biopha.2023.114614_bib39","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1111\/j.1365-2230.2004.01618.x","article-title":"Effects of bepotastine, cetirizine, fexofenadine, and olopatadine on histamine-induced wheal-and flare-response, sedation, and psychomotor performance","volume":"29","author":"Takahashi","year":"2004","journal-title":"Clin. Exp. Dermatol."},{"issue":"21","key":"10.1016\/j.biopha.2023.114614_bib40","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1056\/NEJM199305273282103","article-title":"Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS","volume":"328","author":"Hughes","year":"1993","journal-title":"N. Engl. J. Med"},{"issue":"2","key":"10.1016\/j.biopha.2023.114614_bib41","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S0002-9149(03)00530-7","article-title":"Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial)","volume":"92","author":"Jones","year":"2003","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.biopha.2023.114614_bib42","article-title":"Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods","author":"Wu","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.biopha.2023.114614_bib43","first-page":"eabb3405","article-title":"Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved \u03b1-ketoamide inhibitors","author":"Zhang","year":"2020","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.biopha.2023.114614_bib44","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1021\/ci500681r","article-title":"DOCKTITE-a highly versatile step-by-step workflow for covalent docking and virtual screening in the molecular operating environment","volume":"55","author":"Scholz","year":"2015","journal-title":"J. Chem. Inf. Model"},{"issue":"6","key":"10.1016\/j.biopha.2023.114614_bib45","doi-asserted-by":"crossref","DOI":"10.3201\/eid2606.200516","article-title":"Severe acute respiratory syndrome coronavirus 2 from Patient with 2019 novel coronavirus disease, United States","volume":"26","author":"Harcourt","year":"2020","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.biopha.2023.114614_bib46","article-title":"<em>In vitro<\/em> screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication","author":"Touret","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.biopha.2023.114614_bib47","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00819-20","article-title":"Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs","author":"Jeon","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.biopha.2023.114614_bib48","article-title":"Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells: nafamostat is the most potent antiviral drug candidate","author":"Ko","year":"2020","journal-title":"bioRxiv"},{"issue":"5","key":"10.1016\/j.biopha.2023.114614_bib49","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1093\/jac\/dks504","article-title":"Antimalarial pharmacology and therapeutics of atovaquone","volume":"68","author":"Nixon","year":"2013","journal-title":"J. Antimicrob. Chemother."},{"issue":"1","key":"10.1016\/j.biopha.2023.114614_bib50","doi-asserted-by":"crossref","first-page":"14866","DOI":"10.1038\/srep14866","article-title":"Characterization of plasma protein binding dissociation with online SPE-HPLC","volume":"5","author":"Li","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2023.114614_bib51","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-020-2223-y","article-title":"Structure of M(pro) from COVID-19 virus and discovery of its inhibitors","author":"Jin","year":"2020","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.biopha.2023.114614_bib52","doi-asserted-by":"crossref","first-page":"e00389","DOI":"10.1128\/JVI.00389-19","article-title":"Atovaquone inhibits arbovirus replication through the depletion of intracellular nucleotides","volume":"93","author":"Cifuentes Kottkamp","year":"2019","journal-title":"J. Virol."},{"issue":"7","key":"10.1016\/j.biopha.2023.114614_bib53","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S0006-2952(96)00835-0","article-title":"Effects of dual combinations of antifolates with atovaquone or dapsone on nucleotide levels in Plasmodium falciparum","volume":"53","author":"Yeo","year":"1997","journal-title":"Biochem Pharm."},{"issue":"3","key":"10.1016\/j.biopha.2023.114614_bib54","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1128\/AAC.44.3.713-719.2000","article-title":"Effects of atovaquone and diospyrin-based drugs on the cellular ATP of Pneumocystis carinii f. sp. carinii","volume":"44","author":"Cushion","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"issue":"6554","key":"10.1016\/j.biopha.2023.114614_bib55","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1126\/science.abi4708","article-title":"Drug-induced phospholipidosis confounds drug repurposing for SARS-CoV-2","volume":"373","author":"Tummino","year":"2021","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.biopha.2023.114614_bib56","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s10565-006-0176-z","article-title":"Validation of an in vitro screen for phospholipidosis using a high-content biology platform","volume":"22","author":"Morelli","year":"2006","journal-title":"Cell Biol. Toxicol."},{"issue":"8","key":"10.1016\/j.biopha.2023.114614_bib57","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1093\/cid\/ciw028","article-title":"Efavirenz but not atazanavir\/ritonavir significantly reduces atovaquone concentrations in HIV-infected subjects","volume":"62","author":"Calderon","year":"2016","journal-title":"Clin. Infect. Dis."},{"issue":"6","key":"10.1016\/j.biopha.2023.114614_bib58","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1128\/AAC.42.6.1315","article-title":"Phase I safety and pharmacokinetics study of micronized atovaquone in human immunodeficiency virus-infected infants and children. Pediatric AIDS Clinical Trials Group","volume":"42","author":"Hughes","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"issue":"9","key":"10.1016\/j.biopha.2023.114614_bib59","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.1093\/jac\/dkx198","article-title":"Plasma concentrations of atovaquone given to immunocompromised patients to prevent Pneumocystis jirovecii","volume":"72","author":"Robin","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"issue":"2","key":"10.1016\/j.biopha.2023.114614_bib60","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/BF00542462","article-title":"Clinical pharmacokinetics of high dose mebendazole in patients treated for cystic hydatid disease","volume":"22","author":"Braithwaite","year":"1982","journal-title":"Eur. J. Clin. Pharm."},{"issue":"12","key":"10.1016\/j.biopha.2023.114614_bib61","first-page":"633","article-title":"Serum concentrations of mebendazole in patients with hydatid disease","volume":"23","author":"Bekhti","year":"1985","journal-title":"Int J. Clin. Pharm. Ther. Toxicol."},{"key":"10.1016\/j.biopha.2023.114614_bib62","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1020123","article-title":"Atovaquone for treatment of COVID-19: a prospective randomized, double-blind, placebo-controlled clinical trial","volume":"13","author":"Jain","year":"2022","journal-title":"Front Pharm."},{"key":"10.1016\/j.biopha.2023.114614_bib63","doi-asserted-by":"crossref","first-page":"103","DOI":"10.4137\/CMC.S6677","article-title":"Safety and efficacy of dronedarone in the treatment of atrial fibrillation\/flutter","volume":"5","author":"Naccarelli","year":"2011","journal-title":"Clin. Med. Insights Cardiol."},{"issue":"6","key":"10.1016\/j.biopha.2023.114614_bib64","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1161\/01.CIR.45.6.1176","article-title":"Ouabain pharmacokinetics in dog and man","volume":"45","author":"SELDEN","year":"1972","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.biopha.2023.114614_bib65","doi-asserted-by":"crossref","first-page":"L398","DOI":"10.1152\/ajplung.00398.2016","article-title":"Sialic acid-to-urea ratio as a measure of airway surface hydration","volume":"312","author":"Jr","year":"2017","journal-title":"Am. J. Physiol. -Lung Cell. Mol. Physiol."},{"issue":"2","key":"10.1016\/j.biopha.2023.114614_bib66","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1177\/0192623320929318","article-title":"Aspiration and inspiration: using bronchoalveolar lavage for toxicity assessment","volume":"49","author":"Poitout-Belissent","year":"2021","journal-title":"Toxicol. Pathol."},{"issue":"1","key":"10.1016\/j.biopha.2023.114614_bib67","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00228-002-0426-9","article-title":"Time-dependent pharmacokinetics and drug metabolism of atovaquone plus proguanil (Malarone) when taken as chemoprophylaxis","volume":"58","author":"Thapar","year":"2002","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"21","key":"10.1016\/j.biopha.2023.114614_bib68","doi-asserted-by":"crossref","first-page":"4905","DOI":"10.1039\/c0ob00124d","article-title":"Combination of chiroptical, absorption and fluorescence spectroscopic methods reveals multiple, hydrophobicity-driven human serum albumin binding of the antimalarial atovaquone and related hydroxynaphthoquinone compounds","volume":"8","author":"Zsila","year":"2010","journal-title":"Org. Biomol. Chem."},{"issue":"5","key":"10.1016\/j.biopha.2023.114614_bib69","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/S0009-9236(97)90132-6","article-title":"Population pharmacokinetics of atovaquone in patients with acute malaria caused by Plasmodium falciparum","volume":"61","author":"Hussein","year":"1997","journal-title":"Clin. Pharm. Ther."},{"key":"10.1016\/j.biopha.2023.114614_bib70","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.694300","article-title":"Targeting future pandemics, a case for de novo purine synthesis and basic research","volume":"12","author":"Mazzarino","year":"2021","journal-title":"Front Immunol."},{"issue":"1","key":"10.1016\/j.biopha.2023.114614_bib71","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1021\/ci600406v","article-title":"Solvated interaction energy (SIE) for scoring protein-ligand binding affinities. 1. Exploring the parameter space","volume":"47","author":"Na\u00efm","year":"2007","journal-title":"J. Chem. Inf. Model"},{"issue":"10","key":"10.1016\/j.biopha.2023.114614_bib72","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2016265118","article-title":"Identification of tetracycline combinations as EphB1 tyrosine kinase inhibitors for treatment of neuropathic pain","volume":"118","author":"Ahmed","year":"2021","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"3","key":"10.1016\/j.biopha.2023.114614_bib73","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1111\/cbdd.12963","article-title":"Biological screening of cucurbitacin inspired estrone analogs targeting mitogen-activated protein kinase (MAPK) pathway","volume":"90","author":"Ahmed","year":"2017","journal-title":"Chem. Biol. Drug Des."},{"issue":"10","key":"10.1016\/j.biopha.2023.114614_bib74","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1021\/ci200274q","article-title":"DSX: a knowledge-based scoring function for the assessment of protein-ligand complexes","volume":"51","author":"Neudert","year":"2011","journal-title":"J. Chem. Inf. Model"},{"issue":"36","key":"10.1016\/j.biopha.2023.114614_bib75","doi-asserted-by":"crossref","first-page":"14610","DOI":"10.1073\/pnas.1212379109","article-title":"Dengue reporter viruses reveal viral dynamics in interferon receptor-deficient mice and sensitivity to interferon effectors in vitro","volume":"109","author":"Schoggins","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"23","key":"10.1016\/j.biopha.2023.114614_bib76","doi-asserted-by":"crossref","first-page":"12552","DOI":"10.1128\/JVI.01890-13","article-title":"Middle East respiratory syndrome coronavirus infection mediated by the transmembrane serine protease TMPRSS2","volume":"87","author":"Shirato","year":"2013","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.biopha.2023.114614_bib77","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.pep.2005.01.016","article-title":"Protein production by auto-induction in high density shaking cultures","volume":"41","author":"Studier","year":"2005","journal-title":"Protein Expr. Purif."},{"issue":"3","key":"10.1016\/j.biopha.2023.114614_bib78","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.jmb.2006.11.073","article-title":"Production of authentic SARS-CoV M(pro) with enhanced activity: application as a novel tag-cleavage endopeptidase for protein overproduction","volume":"366","author":"Xue","year":"2007","journal-title":"J. Mol. Biol."},{"issue":"22","key":"10.1016\/j.biopha.2023.114614_bib79","doi-asserted-by":"crossref","first-page":"8951","DOI":"10.1021\/jacs.9b02822","article-title":"Rapid covalent-probe discovery by electrophile-fragment screening","volume":"141","author":"Resnick","year":"2019","journal-title":"J. Am. Chem. Soc."},{"issue":"5","key":"10.1016\/j.biopha.2023.114614_bib80","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1016\/j.celrep.2014.04.037","article-title":"Oxidation of alpha-ketoglutarate is required for reductive carboxylation in cancer cells with mitochondrial defects","volume":"7","author":"Mullen","year":"2014","journal-title":"Cell Rep."},{"issue":"10","key":"10.1016\/j.biopha.2023.114614_bib81","doi-asserted-by":"crossref","first-page":"R100","DOI":"10.1186\/gb-2006-7-10-r100","article-title":"CellProfiler: image analysis software for identifying and quantifying cell phenotypes","volume":"7","author":"Carpenter","year":"2006","journal-title":"Genome Biol."},{"issue":"7","key":"10.1016\/j.biopha.2023.114614_bib82","article-title":"The ARRIVE guidelines 2.0: updated guidelines for reporting animal research","volume":"18","author":"Percie du Sert","year":"2020","journal-title":"PLoS Biol."},{"issue":"8","key":"10.1016\/j.biopha.2023.114614_bib83","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/bdd.325","article-title":"Influence of nonspecific brain and plasma binding on CNS exposure: implications for rational drug discovery","volume":"23","author":"Kalvass","year":"2002","journal-title":"Biopharm. Drug Dispos."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075333222300402X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075333222300402X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T13:31:32Z","timestamp":1778247092000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S075333222300402X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":83,"alternative-id":["S075333222300402X"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2023.114614","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"FDA approved drugs with antiviral activity against SARS-CoV-2: From structure-based repurposing to host-specific mechanisms","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2023.114614","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"114614"}}